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Abstract
Since the worldwide increase in obesity represents a growing challenge for health care systems, new approaches are
needed to effectively treat obesity and its associated diseases. One prerequisite for advances in this field is the identification
of genes involved in adipogenesis and/or lipid storage. To provide a systematic analysis of genes that regulate adipose
tissue biology and to establish a target-oriented compound screening, we performed a high throughput siRNA screen with
primary (pre)adipocytes, using a druggable siRNA library targeting 7,784 human genes. The primary screen showed that 459
genes affected adipogenesis and/or lipid accumulation after knock-down. Out of these hits, 333 could be validated in a
secondary screen using independent siRNAs and 110 genes were further regulated on the gene expression level during
adipogenesis. Assuming that these genes are involved in neutral lipid storage and/or adipocyte differentiation, we
performed InCell-Western analysis for the most striking hits to distinguish between the two phenotypes. Beside well known
regulators of adipogenesis and neutral lipid storage (i.e. PPARc, RXR, Perilipin A) the screening revealed a large number of
genes which have not been previously described in the context of fatty tissue biology such as axonemal dyneins. Five out of
ten axonemal dyneins were identified in our screen and quantitative RT-PCR-analysis revealed that these genes are
expressed in preadipocytes and/or maturing adipocytes. Finally, to show that the genes identified in our screen are per se
druggable we performed a proof of principle experiment using an antagonist for HTR2B. The results showed a very similar
phenotype compared to knock-down experiments proofing the ‘‘druggability’’. Thus, we identified new adipogenesis-
associated genes and those involved in neutral lipid storage. Moreover, by using a druggable siRNA library the screen data
provides a very attractive starting point to identify anti-obesity compounds targeting the adipose tissue.
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Introduction
Obesity is a complex medical condition affecting all populations
and age groups. The rising incidence of obesity has become a
global burden that is not restricted to industrialized countries [1].
According to a recent analysis conducted by the Organization for
Economic Co-operation and Development (OECD), an obesity
epidemic is rapidly escalating in emerging countries such as China,
Mexico or Brazil [2]. Out of this reason, this global epidemic has
been termed a pandemic by the World Health Organization [3].
Since obesity is related to higher rates of cardiovascular diseases,
diabetes, disorders of lipid metabolism and other serious health
problems, resulting social and economic consequences are
multifaceted [2].
Methods for the treatment of obesity consist of dietary
management, physical exercise but gastric surgical interventions
and anti-obesity drugs are employed as well. Pharmacological
drugs promoting weight loss work by different mechanisms of
action: Sibutramine, a selective serotonin and norepinephrine
reuptake inhibitor, e.g. increases the sensation of satiety [4]. The
lipase inhibitor orlistat’s primary function is preventing the
absorption of fats in the gastrointestinal tract, thereby reducing
caloric intake [4]. Currently, the role of drug treatment in obesity
is limited. Since drug therapy is costly and results are often
disappointing, there is a need for more effective and better
tolerated treatments.
Adipose tissue regulates the body’s energy balance. In periods of
energy excess it provides the main energy reserve and at the same
time during phases of food deprivation facilitates fat mobilization.
Obesity is a disorder of energy balance and out of this reason
adipose tissue is a key target to treat this condition. Due to the
increase in obesity-related diseases, an enormous progress has
been made determining the cellular and molecular processes
underlying fat metabolism [5,6]. Nevertheless, so far, actives which
directly target the fatty tissue are rare. To overcome this limitation,
new compounds have to be identified in the near future. One
approach to reach this goal is to characterize new (ideally
druggable) genes/gene products involved in fatty tissue biology.
RNA interference (RNAi) is a posttranscriptional silencing
mechanism which is mediated through small interfering RNAs
(siRNAs) [7,8]. SiRNAs target their complementary mRNA in a
sequence-specific manner, thus reducing the templates for protein
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31193synthesis. The use of the siRNA technique represents a powerful
tool to study phenotypic profiles for specific knock-downs and also
loss of function in cultured cells [9].
A couple of reports describe the performance of RNAi
screenings to investigate the regulation of body fat storage in
model organisms such as Caenorhabditis elegans [10] or Drosophila
[11]. However, to our knowledge, an obesity screening in human
cells has not yet been carried out. To identify new genes involved
in adipogenesis and/or neutral lipid accumulation, we used a
druggable siRNA-library (7,784 genes; 23,352 siRNAs) in
combination with human (pre)adipocytes. Although easier and
less cost-intensive we refrained from using immortalized cell lines
or tumor cells since it is widely accepted that these cells may
deviate from the tissue of origin. To model the in vivo situation as
accurately as possible, we performed all our experiments with
primary human cells. A druggable siRNA library was chosen,
because for most genes/gene products effective compounds,
regulating the action of the corresponding gene, are already
available.
Our screening revealed a large number of genes which have not
been previously described in the context of fatty tissue biology.
Together with published data, our results offer the possibility to
accelerate the development of anti-obesity treatments.
Results
SiRNA screening using primary human (pre)adipocytes
The aim of this study was to identify new genes influencing
human adipogenesis and/or fat accumulation in vitro. For
transfection of primary human preadipocytes, a druggable siRNA
library was used containing 23,352 unique siRNAs targeting 7,784
human genes (three siRNAs per gene).
Successful siRNA transfection requires a cell density of approx.
30–50%, fat cell differentiation on the other hand is optimal at
confluence. To align these experimental conditions, preadipocytes
were siRNA transfected and then, as described earlier [12,13],
cultivated for 3 additional days allowing transfected preadipocytes
to proliferate before differentiation was induced. Eleven days after
cell seeding, DNA content and lipid accumulation of transfected
(pre)adipocytes were determined (Figure 1). Depending on the
siRNA-induced effect, changes in lipid concentration were
observed.
Since peroxisome proliferator-activated receptor c (PPARc) is widely
accepted as a master regulator of adipogenesis [14,15], PPARc-
siRNA was chosen as a positive control for the primary screening.
A pilot study confirmed the knock-down of PPARc both on the
RNA and protein level for several days after transfection using
three different siRNAs (Figures S1A and B, Text S1). The knock-
down efficacy correlated well with decreased neutral lipid
accumulation which is a hallmark for maturing adipocytes (Figure
S1C, Text S1). As negative control a scrambled-siRNA showing
no homology to human genes and a siRNA-free control were
utilized. For experiments, controls were performed in duplicates
per plate, whereas library-associated siRNAs were arrayed in a
one siRNA/one well format. The screen was carried out in a 96-
well plate format to guarantee a cell density exceeding 7,500 cells
which allows for a sufficient number of adipocytes to be studied. As
shown in Figure 1, the outer wells were filled with phosphate
buffered saline (PBS) to reduce edge-effects.
Data correction and screen quality control
Todeterminethecellnumberandtoconsiderpossibledifferences
in proliferation and cell death after knock-down, a Hoechst 33342
staining was performed revealing a linear correlation between the
DNA signal (Hoechst staining) and cell number (propidium iodide
staining) (R
2=0.973; Figure S2A, Text S1). To correct neutral lipid
values for changes in cell number, the DNA signal and the signal
obtained by measurement of lipids were correlated. For the primary
screen and the first validation experiments cells obtained from the
same donor were used and a lipid correction factor of 1.7181 was
determined (R
2=0.9588; N=6, each with 8 data points; Figure
S2Ba, Text S1). For a second validation experiment, using cells
derived from a different donor, we calculated a correction factor of
1.522 (R
2=0.9819; N=6, each with 8 data points; Figure S2Bb).
Accordingly, all neutral lipid values for the primary screen as well as
for each validation experiment (first and second validation
experiment=secondary screening) were adjusted using the corre-
sponding correction factor. As depicted in Figure 2A, prior to
correction of the primary screen, the mean of the Z-scores obtained
for all sample lipid values slightly deviated from the Z-score
determined for lipid values of the scrambled-siRNA control. After
correction, the means of the Z-scores of both distributions
corresponded well. In addition to the corrected Z-score values of
the primary screen the quantile-quantile plot is shown in Figure 2B
to visualize the distribution of each individual value. For
Figure 1. siRNA screening procedure. Two read-out-assays were
performed in 96-well-plates to determine accumulation of neutral lipids
and DNA-content of untransfected and transfected (pre)adipocytes
(N=negative control: control (scrambled) siRNA; P=positive control,
PPARc-siRNA; T=transfection reagent, no siRNA). Outer wells were filled
with PBS to reduce edge effects.
doi:10.1371/journal.pone.0031193.g001
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NPI method (normalized percent inhibition) was employed. To
analyze the performance of the assay during the screen, signals
obtained from positive and negative controls were determined in
relation to plate number. The calculated Z9 factor of 0.42
(Figure 2C) indicated an acceptable screening quality [16],
especially considering that primary cells were used and cultured
for 11 days before read-outs were performed.
After data correction and screen quality control, primary siRNA
hits were determined. To be classified as a hit, a cutoff of a Z-score
greater than 1.5 (lipid accumulation) or lower than -1.5 (lipid
reduction) was selected. In addition, two out of three different
siRNAs having distinct sequences had to display the same
phenotype (lipid accumulation or lipid reduction). Among 7,784
tested genes, 459 genes were identified fulfilling these criteria.
More precisely, 105 of these genes displayed a reduced fat
accumulation during differentiation, whereas for the remaining
354 genes an increased lipid accumulation was observed.
To ensure that the observed phenotypes were caused by
reduced mRNA levels after knock-down, we selected three
different genes identified in our primary screen [(A) Ephrin type-B
receptor 4, EPHB4, (B) protein serine kinase H1, PSKH1 and (C) v-erb-b2
erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived
oncogene homolog (avian), ERBB2] and investigated knock-down
efficiency. After manual siRNA transfection, we determined
neutral lipid accumulation and performed qRT-PCR (Figures
S3A–C, Text S1). Results illustrate that lipid accumulation
correlated well with the data obtained from the primary screening
and reduced mRNA levels were observed after knock-down for all
genes investigated. Furthermore, no loss of viability following
knock-down was detected (data not shown).
Together, these data support the assumption that the majority
of observed phenotypes was caused by a knock-down of the
corresponding gene rather than through off target effects.
To identify functional categories where the hits of the primary
screen accumulated, we performed a series of pathway analyses
using Ingenuity Pathways Analysis (IPA) software. For these initial
analyses, we decided to use the complete set of hits identified,
before performing any additional validation experiment. The
rationale behind this decision was to derive more general
conclusions from our results and to prevent any artificial shift of
the data set caused by stringent selection criteria at this time point.
As detailed in the Materials and Methods section, genes were
mapped to canonical pathways revealing the following most
significant categories: cAMP-mediated signaling, G-protein cou-
pled receptor signaling, and cellular effects of sildenafil (Figure 3A).
Associated network functions of related genes are depicted in
Figure 3B. Among the top 5 networks, two are believed to be
directly involved in lipid metabolism. The network displaying the
highest score (gene expression, developmental disorder, gastroin-
testinal disease; score=37; Figure 3C) shows PPARc – a master
regulator of adipogenesis – as a central gene.
Taken together, the results of the pathway analysis showed that
a variety of proteins known to play a role in adipogenesis and fat
cell metabolism were recognized in the primary screen, increasing
the probability, that genes that have not yet been associated with
adipogenesis and/or fat storage can be identified by this approach.
Secondary screen
Toadditionallyverifytheresultsoftheprimaryscreen,weretested
the 459 identified hits in two independent validation experiments
using new siRNA-sequences and primary cells obtained from two
different donors. In the course of our validation experiments, we
observed for 333 genes (at least for one out of three newly tested
Figure 2. Data correction and quality control of the primary
screen. (A) Correction of neutral lipid values with respect to changes in
cell number. Z-scores of lipid values are illustrated before and after the
amount of DNA was factored in. (B) Q-Q plot of normally distributed
quantiles against screening result (Z-score) quantiles (red circles=po-
sitive control/PPARc-siRNA; blue circles=negative control/scrambled
siRNA). A perfect fit to a normal distribution is represented by red
dotted line. (C) Experiment-wide quality plot focusing on controls.
Signal from positive (red dots; PPARc-siRNA) and negative (blue dots;
control (scrambled) siRNA) controls plotted against plate number. The
distance between the two distributions was quantified by the Z9-factor
(0.42). For data normalization, the method ‘normalized percent
inhibition’ (NPI) was applied.
doi:10.1371/journal.pone.0031193.g002
Obesity Screening Using a Druggable SiRNA Library
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31193siRNAs) a phenotype which resembled the one observed in the
primary screen indicating that the false-positive rate was rather low.
Characterization of identified hits
Axonemal dyneins are involved in fatty tissue biolo-
gy. To characterize the 333 genes in more detail we
performed – similar to the primary screen – pathway analysis
using the Ingenuity software. One of the top scoring IPA
generated networks showed a noticeable accumulation of
axonemal dyneins (Figures 4A). Following knock-down of the
human axonemal dyneins DNAH7 (dynein axonemal heavy chain 7),
DNAH17 (dynein axonemal heavy chain 17), DNAH8,( dynein axonemal
heavy chain 8), DNAH9 (dynein axonemal heavy chain 9) and DNAI2
(dynein axonemal intermediate chain 2) a reduced neutral lipid
accumulation was detected. Interestingly, the knock-down of
kinesins KLC3 (kinesin light chain 3), KIF7 (kinesin family member 7),
KIFC3 (kinesin family member C3) and KIF24 (kinesin family member 24)
resulted in an increased fat accumulation (Figure 4B). An increase
in lipid accumulation was also observed after knock-down of the
cytoplasmic dynein DYNC2H1 (dynein, cytoplasmatic 2, heavy chain1).
In addition, the knock-down of numerous microtubuli-binding or -
associated proteins such as MICAL1 (microtubule associated mono-
xygenase, calponin and LIM domain containing 1), MAP7 (microtubule-
associated protein 7), MAST4 (microtubule associated serine/threonine kinase
family member 4)o rTEKT2 (tektin 2) also caused a change in fat
accumulation during adipogenesis.
To investigate the expression levels of axonemal dyneins during
adipogenesis, we performed qRT-PCR analysis for these genes.
Data showed, that axonemal dynein transcripts of DNAH7,
DNAH8 and DNAH17 are clearly present in (pre)adipocytes (CT-
values between 28 and 34) (Figure 4C), whereas the axonemal
dyneins DNAH9 and DNAI2 are only slightly expressed showing
CT-values between 36 and 37 (Figure S4, and Text S1). To show
that DNAI2 and DNAH9 transcripts are truly expressed in
preadipocytes we performed RT-PCR analysis using RNA
obtained from control cells, DNAI2-siRNA and DNAH9-siRNA
transfected cells, respectively. For independent primer-sets the
results revealed, that in the control lanes (without knock-down) an
amplification of DNAI2 and DNAH9 occurred, which was clearly
reduced in the respective knock-down situation.
Next, we analyzed the siRNA knock-down efficiency for the
dyneins DNAH7, DNAH8 and DNAH17 (Figure S5, Text S1).
Following knock-down of DNAH7, DNAH8 and DNAH17 the
amount of mRNA was only slightly reduced. This effect is at least
partly due to the relatively small basal expression. However, a
decreased mRNA expression after knock-down was detectable for
all axonemal dyneins investigated.
To study the ‘axonemal dynein knock-down phenotype’ in more
detail and to determine whether a knock-down of axonemal
dyneins influences the differentiation process or rather the lipid
turnover, InCell-Western Analyses were carried out utilizing the
adipogenic markers aP2 and Perilipin A (Figure 5A). As a
reference, we used the knock-down of PPARc. As expected,
following knock-down of this master regulator of adipogenesis both
adipogenic markers barely displayed a signal since cells do not
differentiate into the adipogenic lineage without PPARc being
present (Figure 5B). On the basis of the results obtained from the
InCell-Western Analysis, we were able to perform a first
classification of target phenotypes to the following categories
(Figure 5C): (1) target-knock-down that reduced differentiation
Figure 3. Ingenuity Pathways Analysis of positive hits identified in the primary screen. (A) Depicted are the three most significant
canonical pathways with cAMP signaling being the most prominent. (B) Top five associated network functions of related genes. Two of the five top
networks are believed to be directly involved in lipid metabolism. (C) The network displaying the highest score shows PPARc and RXRA, known
regulators of adipogenesis, as central genes.
doi:10.1371/journal.pone.0031193.g003
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stimulated differentiation [aP2 and Perilipin A signals q] and (3)
target-knock-down that caused changes in lipid metabolism [no
significant alterations in aP2 and Perilipin A signals] (for detailed
information please see the Materials and Methods section). Our
data show that the expression of the adipogenic markers (aP2 und
Perilipin A) was strongly decreased only after knock-down of
DNAI2. For DNAH7 and DNAH17 only one marker (aP2 or
Perilipin A) showed expression changes according to our criteria
after knock-down. This implies that at least DNAI2 (and possibly
DNAH7 and DNAH17) play a role in adipogenic differentiation.
In contrast, DNAH8 and DNAH9 may be involved in lipid
turnover. To further characterize axonemal dyneins and their
precise role in adipose tissue biology, we selected DNAI2
(‘‘differentiation phenotype’’ after knock-down) and DNAH8
(‘‘lipid turnover phenotype’’ after knock-down) and performed
low density arrays (LDAs) after siRNA transfection. We analyzed
in total 46 genes known to be involved in adipogenesis and/or
lipid turnover. The results show (Fig. 5D) that in case of DNAI2
knock-down the majority of the adipogenic-relevant transcription
factors are clearly decreased compared to control cells, which is in
good agreement with the ‘‘differentiation phenotype’’ described
above. Differences in mRNA levels after DNAH8- and DNAI2-
knock-down were especially observed for C/EBPd, IL6 and IL1ß.
C/EBPd is known to be involved in adipogenesis [17] but it is also
described in the literature that C/EBPd participates in the
regulation of many genes associated with inflammation [18].
Therefore it can be speculated that in contrast to DNAI2, DNAH8
influences adipose tissue biology by regulating inflammatory
processes. However, further analyses are needed to clarify the
exact role of axonemal dyneins in adipogenesis and fat storage.
Taken together, although DNAH9 and DNAI2 are weakly
expressed, the majority of axonemal dyneins are clearly present in
human primary (pre)adipocytes and reduced mRNA levels could be
detected after knock-down. In total, 30 axonemal dynein-specific
siRNAs were tested for five targets and 17 siRNAs changed the
cellular phenotype in the same manner (reduced lipid accumula-
tion). Although we cannot completely role out off-target effects for
some siRNAs targeting axonemal dyneins, it is conclusive that these
proteins are involved in adipogenesis and lipid accumulation.
Hits that are differentially expressed during adipogene-
sis. To comprehensively analyze whether or not genes validated
in the secondary screen (333 hits) undergo alterations in gene
expression during adipogenesis, microarray analyses were per-
formed. Accordingly, mRNA levels were determined at day 0, day 3
and day 7 after induction of differentiation. During adipogenesis,
110 among the 333 genes were regulated on the gene expression
level (fold change $2o r#22; p#0.01). Specifically, among the
phenotype characterized by a reduced fat accumulation after knock-
down, 9 genes showed an increased expression, whereas 7 genes
provided a reduced expression. In contrast, 40 genes derived from
the second phenotype (augmented lipid accumulation after knock-
down) displayed an increased and 54 a decreased expression during
differentiation (Figure S6 and Text S1). For each phenotype, those
genes showing the most significant expression change during
adiopgenesis are depicted in Table 1 (A and B).
Figure 4. Network of axonemal dyneins. (A) Dynein network: The green coloring indicates 4 out of 5 hits regarding axonemal dyneins. DNAH7
(also identified in our screen) was not part of the network. Blue symbols represent dyneins which were part of the library but were not determined as
hits. Dyneins colored in white could not be investigated using the druggable siRNA library. (B) IPA showed an accumulation of motor proteins
including dyneins and kinesins. (C) Messenger RNA levels of DNAH7, DNAH8 and DNAH17 in the course of adipocyte differentiation. Expression data at
day 0 (preadipocytes) were set as 100%. All CT-values analyzed were between 28 and 34.
doi:10.1371/journal.pone.0031193.g004
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bona fide adipogenesis or lipid accumulation we conducted an
InCell-Western Analysis as described above (for detailed informa-
tion see Material and Methods). The results indicate that for 7
genes (out of 16), showing a decreased lipid accumulation after
knock-down, a reduced fat cell differentiation rate (indicated by a
decreased aP2 and Perilipin A signal) could be detected. This
implies that reduction in neutral lipid accumulation might rather
be attributed to a decreased differentiation-efficacy than to a shift
of the lipogenesis/lipolysis ratio, although an involvement of both
processes cannot be completely ruled out (Figure 6, upper box,
green arrows, marked in grey). For the remaining targets (except
DLX4, KRT79 and OAZ3) no changes in aP2 and Perilipin A
expression could be observed after knock-down. Therefore the
decrease in lipid accumulation detected after knock-down of these
genes might be attributed to a shift of the lipogenesis/lipolysis ratio
towards lipolysis without differentiation being affected (Figure 6,
upper box, no arrows, marked in yellow). It should be noted that
for none of the genes showing this specific phenotype after knock-
down (reduced lipid accumulation) an increase in differentiation
rate could be detected (Figure 6, upper box).
The same classification was conducted for the second phenotype
observed in our screen, i.e. increased lipid accumulation after
knock-down. The corresponding results are illustrated in Figure 6,
lower box. For two of the targets we could observe a clear increase
in differentiation after knock-down (Figure 6, lower box, red
arrows marked in grey) which probably caused the observed
phenotype (augmented lipid accumulation). For 10 targets we
detected a change in ‘differentiation’ after knock-down that was
only supported by one marker (aP2 or Perilipin A) or in case of
PPAPDC1A-silencing, aP2 signal increased while Perilipin A
signal decreased. For this target set additional experiments are
needed to distinguish between adipogenesis and/or lipid storage.
For the remaining genes no changes in aP2/Perilipin A signals
could be detected (Figure 6, lower box, no arrows, marked in
yellow) after knock-down, which we explain by a shift of the
lipogenesis/lipolysis ratio towards lipogenesis.
Druggable targets
In our experiments we used a druggable siRNA library. For the
majority of genes targeted by siRNAs of this library, compounds
modulating the activity of their gene product are already available.
Figure 5. Knock-down of axonemal dyneins and classification of corresponding phenotypes. InCell-Western Analyses were performed
using aP2- and Perilipin-specifc antibodies. (A) Depicted are immunofluorescence images showing aP2 and Perilipin stainings. (B) InCell-Western-
Image using aP2 and Perilipin antibodies showing PPARc knock-down (rimmed in red) and scrambled siRNA edged in blue. (C) Classify of ‘target
phenotypes’ into the following categories: (1) target-knock-down that reduce differentiation, [aP2 and Perilipin A signals decreased $20% compared
to controls, green arrow]; (2) target-knock-down that stimulate differentiation [aP2 and Perilipin A signals increased $20% compared to controls, red
arrow] and (3) target-knock-down that caused no changes in differentiation [no significant changes in aP2 and Perilipin signals]. For targets
highlighted in grey, signals of both markers decreased or increased. For those targets under laid in yellow, none marker changed. (D) Messenger RNA
levels of adipocyte-relevant transcription factors as well as IL6 and IL1ß after DNAI2- and DNAH8 knock-down. Differentiation was initiated 3 days
after transfection. The qRT-PCR was performed on day 5 post-transfection. Results are depicted as mean 6 SD.
doi:10.1371/journal.pone.0031193.g005
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compound screening is per se possible, a proof of principle
experiment was conducted. Therefore, we selected HTR2B (5-
hydroxytryptamine (serotonin) receptor 2B), a serotonin receptor which
was one of our top hits identified and validated in our screening
(see Table 1). Cells cultured in the presence of a commercially
available antagonist of HTR2B (RS127445) exhibited significantly
increased neutral lipid levels of 139 (617)% compared to control
cells (set as 100%; p#0.0001; Figure 7A) without affecting cell
viability (Figure 7B). As illustrated by the prominent yellow
staining in Figure 7C, the majority of cells treated with 50 mM
RS127445 accumulated neutral lipids. In contrast, control cells
showed only a moderate staining. After incubation with the
HTR2B antagonist, cells displayed a phenotype (increased fat
accumulation) which had already been observed after receptor
knock-down.
Table 1. Genes identified in the primary and validated in the secondary screen displaying a strong change in mRNA expression
(determined by microarray analysis) during adipogenesis on day 3 or on day 7 compared with preadipocytes (d0).
A Phenotype: decreased lipid accumulation
Gene Name Accession no. Fold change p-value
perilipin 1 [PLIN1] NM_002666 .100 ,1E-45
inter-alpha (globulin) inhibitor H1 [ITIH1] NM_002215 .100 ,1E-45
peroxisome proliferator-activated receptor gamma [PPARG] NM_138711 32.36 ,1E-45
ring finger protein 150 [RNF150] NM_020724 12.32 1.24E-08
distal-less homeobox 4 [DLX4] NM_138281 8.65 1.45E-06
sphingosine-1-phosphate receptor 3 [S1PR3] NM_005226 4.05 1.47E-11
frizzled homolog 3 (Drosophila) [FZD3] NM_017412 3.77 8.60E-04
hydroxysteroid (17-beta) dehydrogenase 12 [HSD17B12] NM_016142 3.73 9.77E-35
glucuronidase. beta [GUSB] NM_000181 2.24 1.18E-11
multiple EGF-like-domains 6 [MEGF6] NM_001409 281.28 ,1E-45
integrin. alpha 3 (antigen CD49C. alpha 3 subunit of VLA-3 receptor) [ITGA3] NM_002204 213.85 1.77E-20
v-myb myeloblastosis viral oncogene homolog (avian)-like 2 [MYBL2] NM_002466 29.12 7.60E-29
keratin 79 [KRT79] NM_175834 23.64 5.60E-04
integrin. alpha 6 [ITGA6] NM_000210 22.86 1.40E-04
ornithine decarboxylase antizyme 3 [OAZ3] NM_016178 22.68 6.75E-16
retinoblastoma 1 [RB1] NM_000321 22.00 3.50E-34
B Phenotype: increased lipid accumulation
Gene Name Accession no. Fold change p-value
phosphodiesterase 3B. cGMP-inhibited [PDE3B] NM_000922 .100 ,1E-45
stearoyl-CoA desaturase (delta-9-desaturase) [SCD] NM_005063 .100 ,1E-45
angiotensinogen (serpin peptidase inhibitor. clade A. member 8) [AGT] NM_000029 93.86 ,1E-45
RASD family. member 2 [RASD2] NM_014310 87.29 ,1E-45
mevalonate (diphospho) decarboxylase [MVD] NM_002461 19.24 1.40E-45
dihydrolipoamide S-acetyltransferase [DLAT] NM_001931 11.30 2.13E-43
phosphodiesterase 4D. cAMP-specific [PDE4D] NM_006203 9.92 5.39E-37
solute carrier family 29 (nucleoside transporters). member 2 [SLC29A2] NM_001532 9.89 2.36E-32
matrix Gla protein [MGP] NM_000900 9.12 4.08E-23
ret proto-oncogene [RET] NM_020975 8.24 7.81E-06
fibroblast growth factor 1 (acidic) [FGF1] NM_000800 285.29 ,1E-45
regulator of G-protein signaling 4 [RGS4] NM_005613 263.05 ,1E-45
G protein-coupled receptor 56 [GPR56] NM_201525 251.50 1.53E-19
RAB3B. member RAS oncogene family [RAB3B] NM_002867 250.39 9.16E-17
CXCR2 chemokine (C-X-C motif) receptor 2 [IL8RB] NM_001557 226.95 2.00E-05
histamine receptor H1 [HRH1] NM_000861 221.27 ,1E-45
ADAM metallopeptidase with thrombospondin type 1 motif. 14 [ADAMTS14] NM_139155 221.05 1.85E-24
5-hydroxytryptamine (serotonin) receptor 2B [HTR2B] NM_000867 212.25 1.81E-11
nuclear receptor subfamily 1. group D. member 1 [NR1D1] NM_021724 210.40 9.42E-24
phosphatidic acid phosphatase type 2 domain containing 1A [PPAPDC1A] NM_001030059 28.00 8.99E-06
doi:10.1371/journal.pone.0031193.t001
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screening is technically feasible. Since for most druggable gene
products agonists or antagonists are already available, this approach
represents a powerful tool for the development of new pharma-
ceuticals for a particular field of research in a shorter time period.
Discussion
To provide a systematic analysis of genes that regulate human
fat cell differentiation and/or lipid accumulation, we performed a
siRNA screen using a druggable siRNA library. Although cell lines
Figure 6. Genes identified and validated in our siRNA-screening showing the most significant changes in gene expression during
adipogenesis were again transfected with specific siRNAs to classify the corresponding phenotype. Knock-down of genes caused a
decreased lipid accumulation (upper box) or increased lipid accumulation (Lower box). InCell-Western Analyses were performed using aP2- and
Perilipin-specific antibodies to classify target phenotypes into the following categories: (1) target-phenotype that reduce differentiation, [aP2 and
Perilipin A signals decreased $20% compared to controls, green arrow]; (2) target-knock-down that stimulate differentiation [aP2 and Perilipin A
signals increased $20% compared to controls, red arrow] and (3) target-phenotype that caused no changes in differentiation [none alterations in aP2
and Perilipin signals]. For targets highlighted in grey, signals of both markers decreased or increased. For those targets under laid in yellow, none
marker changed.
doi:10.1371/journal.pone.0031193.g006
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to study fat metabolism [19], known species-related differences in
adipose tissue biology and also cell line-related artifacts have to be
taken into account. Out of these reasons, we utilized primary
cultured human (pre)adipocytes throughout our experiments as
these cells represent an in vitro model depicting the human situation
more accurately.
In the primary screen two categories of hits were identified:
those that accelerate adipogenesis and/or increase lipid accumu-
lation and those that inhibit/delay adipogenesis and/or decrease
lipid incorporation. To analyze these hits in more detail, we
preformed pathway analysis. The results revealed that the highest
scoring interactive network displayed PPARc as a central gene.
Together with its co-receptor RXR (retinoic X receptor), which was
also identified in our primary screen, PPARc forms heterodimers to
bind DNA and activate transcription of adipocyte relevant genes
to induce fat cell differentiation [5,6,20,21]. In addition to PPARc
and its interacting proteins a variety of well known genes involved
in adipose tissue biology (like Perilipin A etc.) were identified in
our initial screen supporting the idea, that the primary screen
produced reliable results. To further characterize and validate the
identified hits we performed a secondary screen using independent
siRNAs and cells from a different donor. The results showed that
more than 70% of the candidate hits (333/459 genes) could be
validated at least with one new siRNA showing that the false-
positive rate was rather low.
Besides the well known players in fatty tissue biology, our screen
also revealed a vast array of targets which so far have not been
implicated in adipogenesis and/or lipid metabolism. Among these
genes are motor proteins. Whereas cytoplasmatic dyneins and
kinesins are already described in the literature to be involved in
lipid-droplet transport along microtubules [22–25], axonemal
dyneins have to our knowledge not previously been implicated in
the context of adipocyte differentiation and/or neutral lipid
storage. Therefore, our results show for the first time an
involvement of this gene family in adipogenesis and/or lipid
metabolism. Axonemal dyneins are described to be part of the so
called axoneme, a structure that is found in cilia and flagella. In
the axoneme these motor proteins mediate cilia or flagella
movement by sliding microtubules along each other [26]. In
contrast to these mobile cilia, primary ‘‘immobile’’ cilia exist.
Many vertebrate cells create a single primary cilium in their life
which was long ignored in the research community because it was
thought to be just an artifact of evolution. More recently it was
shown, that these structures could act as sensory antennae,
transferring signals from the outside to the inside of a cell [27].
Primary cilia are formed in MSCs (mesenchymal stem cells) and
the knock-down of Polaris (a protein that is localized to the basal
body of a primary cilium) inhibits adipogenic and osteogenic
differentiation. However, cells transfected with Polaris-siRNA
showed a deficiency in adhesion and subsequently detached from
the culture dish [28]. This phenotype was not observed in our
experiments, suggesting that axonemal dyneins act through a
different pathway. This assumption is further supported by the fact
that usually axonemal dyneins are missing in primary cilia [29].
Future studies need to be carried out to investigate the role of
axonemal dyneins in adipogenesis and/or neutral lipid metabolism
in more detail.
Since we used a druggable library, the activity of most of these
genes/gene products can be influenced by a (known) agonist or
an antagonist. Out of this reason, these genes can be considered
as potential targets for therapeutics. Conducting a proof of
principle experiment, we inhibited the serotonin receptor HTR2B
during adipogenesis using its commercially available antagonist
RS127445 and investigated the effects on neutral lipid accumu-
lation. Cells incubated in the presence of the antagonist showed
an increased fat accumulation, similar to the knock-down
phenotype, supporting the idea that a target-oriented compound
screening is feasible. The Ingenuity Pathways Analysis software
(Ingenuity Systems, Mountain View, CA, USA) or platforms such
as The GeneCards Human Gene Database (Crown Human
Genome Center, Department of Molecular Genetics, the
Weizmann Institute of Science, Rehovot, Israel) allow a quick
overview regarding available agonists and antagonists. Therefore,
the results of this screen should accelerate compound identifica-
tion. Moreover, the fact, that we also identified new pathways
and genes involved in adipose tissue biology bears the interesting
opportunity to modulate adipogenesis and/or fat cell differenti-
ation at different levels preventing potential cellular compensa-
tory mechanisms.
In conclusion, we identified new genes playing a role in
adipogenesis and/or neutral lipid accumulation. Since we used a
druggable siRNA library, results provide a resource for the
development of novel anti-obesity compounds targeting the fatty
tissue. In addition, results could be used to improve ex vivo fat cell
differentiation aiming to assist in the generation of mesenchymal
tissue used as a graft in severe cancer cases.
Figure 7. Effects of the HTR2B-antagonist RS127445 on neutral
lipid accumulation during human primary (pre)adipocyte
differentiation. (A) Increase in lipid concentration in maturing
adipocytes after treatment with 50 mM RS127445. Neutral lipid
accumulation is shown relative to untreated control cells set as 100%.
Results are depicted as mean 6 SD (n=10). Significant differences are
marked with an asterisk (* for p,0.0001). (B) Cell viability of
differentiating adipocytes after treatment with 50 mM RS127445 is
shown relative to untreated control cells set as 100%. Results are
depicted as mean 6 SD. (C) Fluorescence microscopy after incubation
with or without 50 mM RS127445 and lipid staining (yellow: neutral
lipids; scale bar: 200 mm).
doi:10.1371/journal.pone.0031193.g007
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Cell culture
Subcutaneous human preadipocytes isolated from thighs of
different healthy female subjects were obtained from Zen-bio Inc.
(Research Triangle Park, NC, USA). Cells were cultured as
previously described [30]. Briefly, cells were incubated in basal
growth medium (PT-8200; Lonza, Verviers, Belgium) containing
10% fetal calf serum (PAA, Pasching, Austria), 2 mM L-
glutamine, 100 U/ml penicilline and 100 mg/ml streptomycine
(all obtained from Gibco BRL, Eggenstein, Germany). This
medium is designated as culture medium. Differentiation into
adipocytes was initiated by addition of 10 mg/ml insulin, 1 mM
dexamethasone, 200 mM indomethacin and 500 mM isobutyl-
methylxanthine (PT-9500; Lonza) to the medium. Culture
medium containing these ingredients is designated as differentia-
tion medium. For our studies we used cells up to the third passage.
SiRNA transfection
High-throughput siRNA screening (primary screen).
SiRNAs were loaded into multiwell cavities (3.6 ml/well; 2.5 mM)
and diluted in OPTI-MEM I and GlutaMAX I medium (Gibco
BRL) to a final volume of 15 ml. Following dilution of the
transfection reagent Lipofectamine 2000 (Invitrogen, Karlsruhe,
Germany) (0.27 mli n1 5ml OptiMEM I and GlutaMAX I), the
resulting solution was incubated for at least 5 min, then combined
with the siRNA solution and gently mixed. After an additional
incubation for 20 min, 30 ml of the transfection reagent-siRNA
complex were transferred to 96-well plates already containing
adherend subcutaneous human preadipocytes (7,500 cells/well in
120 ml culture medium). Consequently, the final siRNA
concentration was 60 nM.
Cells were incubated at 37uC and 5% CO2 for 3 days, before
adipogenesis was induced by substitution of the medium with
differentiation medium. After 7 additional days of incubation, the
phenotype was determined. For that purpose, the total amount of
accumulated lipids (see below) was determined and an indirect
cell count (see below) was carried out by means of DNA staining.
Multi-well pipetting was performed using the Biomek NX
P
Laboratory Automation Workstation (Beckman Coulter, Brea,
CA, USA). For transfection experiments, a siRNA library
(SilencerH Human Druggable Genome siRNA Library V3, 384-
well plates, Ambion, Darmstadt, Germany) containing the
druggable human genome [31] with 3 different siRNAs per
targeted gene was used. The entire library was screened once.
The following siRNAs were used on every screening plate as
controls: PPARc-siRNA (Hs_PPARG_1_HP siRNA) und AllStars
Negative Control siRNA (both obtained from Qiagen, Hilden,
Germany).
Validation of identified hits (secondary screen). The
entirety of hits identified in the primary screen (459 genes) was
retested using a miniature siRNA-library (3 independent siRNA-
sequences per gene). For this validation, we used SilencerH Select
siRNAs (Ambion) in a final concentration of 40 nM (optimal
siRNA concentration was determined in pilot-experiments, data
not shown). SiRNA transfection was performed according to the
primary screen in the 96-well plate format using the Biomek NX
P
Laboratory Automation Workstation. The screen utilizing the
miniature library was carried out in two independent experiments
and with two preadipocyte-populations isolated from two different
donors. The following siRNAs were used on every screening plate
as controls: PPARc-siRNA (s10886) und Silencer Select Negative
Control siRNA #1 (4390843; both obtained from Ambion).
Neutral lipid and DNA staining
For the primary and secondary screen, the Biomek NX
P
Laboratory Automation Workstation was employed to perform the
staining.
Following induction of differentiation, cells were cultured for 7
days in 96-well plates. For lipid and parallel cell nuclei staining,
cells were washed with 200 ml/well 16PBS (PAA). Next, 200 ml/
well 16PBS containing 5 mg/ml Hoechst 33342 (Invitrogen) were
added to the cells. After that, 5 ml AdipoRed
TM (Lonza) were
added to each well staining the intercellular lipid droplets. In these
droplets cells store triacylglycerols, sterol esters and other neutral
lipids [32]. After incubation for 30 min at 37uC and 5% CO2,
fluorescence signals (AdipoRed: Ex 485/20, EM 575/15; Hoechst
33342: Ex 330/80, Em 470/40) were determined using the
microplate reader Synergy 4 (BioTek Instruments GmbH, Bad
Friedrichshall, Germany).
qRT-PCR/Low Density Array
Total RNA was isolated using TRIzolH (Invitrogen) and
subsequently treated with TURBO
TM DNase (Ambion) according
to the manufacturer’s protocols. After reverse transcription with
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Darmstadt, Germany), samples were analyzed by
Real-Time TaqManH-PCR using the 7900HT Fast-Real-Time
PCR System (Applied Biosystem).
FAM labelled primers for the qRT-PCR (Applied Biosystems)
were as follows: Single TaqMan Assays [DNAH7 (Hs01022427_
m1), DNAH8 (Hs00241946_m1) and DNAH17 (Hs01116044_m1)]
and TaqMan Assays loaded into micro fluidic cards/Low Density
Array [PPARc (Hs00234592_m1), ADD1 (Hs01088691_m1), C/
EBPa (Hs00269972_s1), C/EBPb (Hs00270923_s1), C/EBPd
(Hs00270931_s1), IL6 (Hs00985639_m1) and IL1b (Hs00174097_
m1)]. The PCR was performed as recommended by the supplier.
Data were analyzed utilizing the Sequence detector version 2.3
software supplied with the 7900 Sequence Detector and RQ
Manager 1.2. Quantification was achieved using the 2
2DDCt
method which calculates the relative change in gene expression of
the target normalized to an endogenous reference (GAPDH;
Hs99999905_m1).
RNA preparation and Microarray analysis
To investigate gene expression changes during adipogenesis of
genes identified in the primary screen, samples were analyzed
using the Agilent 014850 Whole Human Genome Microarray
4644K one-color chip (Agilent Technologies, Bo ¨blingen, Ger-
many). Subcutaneous human preadipocytes were seeded into 6-
well plates (300,000 cells/well). The following day, RNA was
isolated from some of the samples (d0), while adipogenesis was
initiated in the remaining samples by adding differentiation
medium. Three (d3) and 7 days (d7) after induction of
differentiation the respective cells were subjected to RNA isolation
using TRIzolH (Invitrogen) and subsequently treated with
TURBO
TM DNase (Ambion) according to the manufacturer’s
protocols. In total, three different points in time during
adipogenesis were investigated. This experiment was carried out
with cells obtained from three different donors. Quality control of
samples as well as performance and analysis of experiments was
carried out by Miltenyi Biotech GmbH (Bergisch Gladbach,
Germany).
RNA quality and integrity were determined using the Agilent
RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent
Technologies). RNA was quantified by measuring A260 nm on
the ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA).
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Microarray-Based Gene Expression Analysis’’ protocol (version
5.7, part number G4140-90040). Briefly, 1 mg of each total
RNA sample was used for the amplification and labeling step
using the Agilent Quick Amp Labeling Kit (Agilent Technol-
ogies) in the presence of cyanine 3-CTP (Perkin Elmer,
Waltham, MA, USA). Yields of cRNA and the dye-incorpora-
tion rate were measured with the ND-1000 Spectrophotometer
(NanoDrop Technologies).
The hybridization procedure was performed according to
the ‘‘One-Color Microarray-Based Gene Expression Analysis’’
protocol (version 5.7 part number G4140-90040) using the
Agilent Gene Expression Hybridization Kit (Agilent Technol-
o g i e s ) .B r i e f l y ,1 . 6 5 mg Cy3-labeled fragmented cRNA in
hybridization buffer was hybridized overnight (17 h, 65uC) to
Agilent Whole Human Genome Oligo Microarrays 4644K
using Agilent’s recommended hybridization chamber and
oven. Following hybridization, the microarrays were washed
once with the Agilent Gene Expression Wash Buffer 1 for
1 min at room temperature followed by a second wash with
preheated Agilent Gene Expression Wash Buffer 2 (37uC) for
1 min. The last washing step was performed with acetonitrile
for 30 sec.
Fluorescence signals of the hybridized Agilent Microarrays were
detected using Agilent’s Microarray Scanner System G2505C with
a resolution of 5 mm.
The Agilent Feature Extraction Software (FES) version 10.5.1.1
was used to read out and process the microarray image files. For
determination of differential gene expression FES derived output
data files were further analyzed using the Rosetta ResolverH gene
expression data analysis system (Rosetta Biosoftware, Cambridge,
MA, USA) [33].
The following ratios were determined: d0 vs. d3 and d0 vs. d7
(n=3). The prerequisite for a gene to be considered as a regulated
gene during adipogenesis was determined as follows: at least one
probe per gene and at least one transcript variant per gene for the
ratios d0 vs. d3 and d0 vs. d7 needed to show a fold change $2o r
#22 and p#0.01.
Microarray accession number
The MIAME compliant Microarray data discussed in this
publication have been deposited in NCBI’s Gene Expression
Omnibus [34] and are accessible through GEO Series accession
number GSE28628.
In-Cell Western (ICW)/Immunofluorescence microscopic
analysis
For In-Cell Western analysis, (pre-)adipocytes were fixed with
4% formaldehyde solution for 15 min at room temperature,
washed with PBS and permeabilized with 0.2% Triton X-100
(5 min). After successive washing with PBS, fixed cells were pre-
treated with PBS containing 10% donkey serum for 30 min. Cells
were then incubated for 1 h with primary antibodies directed
against adipogenic markers (Anti-FABP4/aP2, HPA002188 or
Anti-Perilipin A, P1998; both obtained from Sigma) and GAPDH
(sc-47724; Santa Cruz, Heidelberg, Germany). Cells were
successively rinsed three times with PBS, and then incubated for
1 h with secondary antibodies labelled with IRDye680 respectively
IRDye-800. Results were determined using the Odyssey Infrared
Imager (Li-Cor Biosciences, Bad Homburg, Germany). In-Cell
Western analyses were performed after knock-down experiments
and after induction of differentiation. Cells were processed on day
four (aP2 staining) and on day five (Perilipin staining) after
induction of differentiation. For data interpretation, the signal
intensities of the adipogenic markers were first normalized to the
endogenous reference (GAPDH). Accordingly, the NPI method
(normalized percent inhibition) was applied (non-targeting con-
trol=scrambled siRNA; inhibitor control=PPARc siRNA). The
threshold was determined as a deviation of +/220% from the
value of the ‘non-targeting control’. A hit was considered as
validated provided at least two out of three siRNAs per gene
exceeded or dropped below the predefined threshold value. The
results were classified as follows: (1) In case that the knock-down of
a target gene decreased the expression of aP2 and Perilipin A
about more than 20% compared to their expression in control
cells, targets were rated as causing a ‘reduced differentiation’. (2)
In case that the knock-down of a target gene led to an increased
expression of aP2 and Perilipin A (.20% compared to control),
targets were rated as causing an ‘increased differentiation’. (3)
Target-knock-down showing no significant expression changes
with respect to aP2 and Perilipin A expression (,+/220%
compared to control after knock-down) were rated as ‘differenti-
ation was not affected’. Please note, only if both markers shifted
within the defined settings/criteria, the described classification had
been applied.
The analysis was carried out in two independent experiments
and with two preadipocyte populations isolated from two different
donors. In addition to the ICW analyses, immunofluorescence
microscopic analyses were performed by using secondary anti-
bodies labelled with Cy3. Results were determined using the
Fluorescence microscope IX71 in combination with the software
cell‘F v. 2.4 (Olympus, Hamburg, Germany).
Compound Treatment
(Pre)adipocytes were cultured in 96-well plates (10,000 cells/
well) in differentiation medium (PGM-2, PT-8002, Lonza)
containing 50 mM of the HTR2B antagonist RS127445 (2993,
Tocris Bioscience, Ellisville, MO, USA) for 7 days. Afterwards
lipid accumulation was determined using the AdipoRed
TM assay
according to the manufacturer’s instruction. Fluorescence was
detected at 572 nm using the microplate reader Infinite-M 200
(Tecan). A viability assay determining the endogenous esterase
activity was used to evaluate possible cytotoxic effects of
compound treatment (RS127445). Briefly, 7 days after induction
of differentiation, cells were washed with 16PBS and incubated
for 20 min at 37uC and 5% CO2 with 100 ml/well of a fluorescein
diacetate (FDA) (Sigma, Taufkirchen, Germany) solution (15 mg/
ml FDA in 16 PBS). Fluorescence was determined at 517 nm
using the microplate reader infiniteH M200 (Tecan, Crailsheim,
Germany).
Data analysis (primary and secondary screen)
For an unbiased interpretation of the primary screen, a lipid data
correction factor was determined. This step was performed to reduce
the influence of plate effects and siRNA knock-down on
proliferation and cell viability. Corrected lipid data were
statistically evaluated using the cellHTS2 software [35] imple-
mented in Bioconductor/R for the analysis of cell-based high-
throughput RNAi screens. For this purpose, corrected raw data
were normalized using the NPI method (normalized percent
inhibition) in order to factor in the varying transfection efficiency
in different plates. In an additional step, the Z-score-transforma-
tion was applied to assign a score to the normalized data taking
into account the scattering of data points over all screen plates. Z-
score-transformed data were then used for a redundant siRNA
activity analysis (RSA) [36]. The RSA applies a rang-based
hypergeometric distribution test for hit analysis. To be considered
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two out of three screened siRNAs.
To minimize the risk of misinterpretation of gene activity for the
secondary screen, we also applied the cellHTS2 software for
statistical data analysis. In contrast to the primary screen, we did
not perform a Z-score-transformation, NPI normalized data were
directly used for the subsequent RSA. The threshold was
determined as a deviation of +/220% from the value of the
‘non-targeting control’. A hit was considered as validated provided
at least one siRNA per gene exceeded or dropped below the
predefined threshold value.
Gene function and network analysis
For pathway analysis and analysis of gene functions and
networks the Ingenuity Pathways Analysis (IPA) software, version
6.3 (IngenuityH Systems, http://www.ingenuity.com) was used.
Positive hits were analyzed in combination with the ranking
information obtained from the previously performed RSA. IPA
settings for analyses were as follows: Use of gene information
without limitation through species, tissues or cell lines; for network
analysis (max. 35 molecules/network), direct and indirect relations
were taken into account; for analyses all available ‘‘data sources’’
provided by IPA were considered.
Statistical analysis
A significance level of 0.05 (alpha) was chosen for statistical
analysis, based on two-sided hypothesis testing. The following
analysis for paired samples was performed: (1) Check of normal
distribution of pair’s differences by means of Shapiro-Wilk’s test;
(2) Comparison versus control by paired sample T-test.
For analysis, STATISTICA 9.1 software (StatSoft. Inc., Tulsa,
OK, USA) was used.
Supporting Information
Figure S1 Determination of PPARc knock-down efficacy
and characterization of the resulting phenotype. Human
primary preadipocytes were transfected with three different
PPARc-siRNAs and differentiation was initiated after 3 days. (A)
PPARc knock-down was confirmed using qRT-PCR (5 days post-
transfection) and (B) Immunoblot analysis (6 days post-transfec-
tion). (C) Effects on lipid accumulation after PPARc knock-down
was detected 10 days after siRNA transfection. Lipid accumulation
is shown relative to control cells incubated with scrambled-siRNA
(control siRNA) set as 100%. Results are depicted as mean 6 SD
(n=6).
(TIF)
Figure S2 Quality check of read-out methods and
determination of lipid data correction factors. (A) Scatter
plot between the DNA signal and the number of cells showed a
linear correlation (R
2=0.973). Following Hoechst 33342 stain,
DNA was determined using a plate reader. The number of cells
was counted with an automated fluorescence microscope after
propidium iodide staining. (B) Scatter plots between DNA and
lipid signals showed a linear correlation for cells of two different
donors. Six independent experiments with eight data points were
prepared. (a) The slope of the regression line indicates the lipid
data correction factor (1.7181) for the primary screen and the first
validation experiment (part of the secondary screen). (b) The slope
of the regression line indicates the lipid data correction factor
(1.522) for the second validation experiment (part of the secondary
screen).
(TIF)
Figure S3 Knock-down efficacy and resulting phenotype
of selected hits identified in the primary screen. (A)
EPHB4, (B) PSKH1 and (C) ERBB2. Lipid accumulation according
to the primary screen and after manual transfection determined
for the three selected genes A–C. Manual siRNA transfection was
performed for each selected gene using the 3 different siRNAs
utilized in the primary screen. Differentiation was initiated 3 days
after transfection. Results are depicted as mean 6 SD (n=6). To
determine knock-down efficacy, qRT-PCR was performed on day
3 (d3) and day 5 (d3+2) post-transfection.
(TIF)
Figure S4 Expression of DNAI2 and DNAH9 in (pre)-
adipocytes. (A) CT values obtained by qRT-PCR analysis. (B)
Amplification of DNAI2- and DNAH9 transcripts isolated from
knock-down as well as from control transfected (scrambled siRNA)
cell populations. Depicted are the PCR products, using two
independent primer sets. (C) Lipid accumulation of DNAI2- and
DNAH9 knock-down populations compared to controls (set as
100%).
(TIF)
Figure S5 Knock-down efficacy and resulting phenotype
after siRNA transfection using axonemal dynein-specific
siRNAs. (A) DNAH7, (B) DNAH8 and (C) DNAH17. Lipid
accumulation according to the screen and after manual transfec-
tion determined for the three selected genes A–C (n=6). Manual
siRNA transfection was performed for each selected gene using
those siRNAs showing a phenotype in the primary screen.
Differentiation was initiated 3 days after transfection. Results are
depicted as mean 6 SD. To determine knock-down efficacy, qRT-
PCR was performed on day 5 (d3+2) post-transfection. (DNAH7:
n=2; DNAH8 and DNAH17: n=3).
(TIF)
Figure S6 Messenger RNA expression during adipogen-
esis of hits validated in the secondary screen. Messenger
RNA levels were determined by microarray analysis at different
time points during adipogenesis (day 0, day 3 and day 7). Depicted
is the number of hits displaying an increased (q) or decreased (Q)
gene expression level compared with preadipocytes (fold change
$2o r#22; p#0.01).
(TIF)
Text S1 Material and methods for experiments pro-
vided in the ‘‘supporting information’’ section. A
detailed description is given for: Cell culture and siRNA
transfection, qRT-PCR, Immunoblotting, reverse transcription
PCR and agarose gel electrophoresis, neutral lipid accumulation,
DNA staining, microarray analysis and determination of the lipid
correction factors.
(DOC)
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